On May 24, 2010 the FDA approved Genzyme’s Lumizyme for the treatment of patients with Pompe disease who are over 8 years of age and do not have evidence of cardiac hypertrophy.
For more information on the approval and how to access treatment, please read the Pompe Program Update.